What Fasenra Treats: Main Uses and Benefits

Fasenra (Benralizumab) is commonly used as an add-on maintenance treatment for individuals with severe eosinophilic asthma in situations where the condition is not adequately controlled by high-level standard therapies. This approach is applied across therapeutic domains involving symptoms that become more disruptive during flare-ups, with the main benefit being that it may assist with maintaining a more manageable rate of severe asthma exacerbations, which helps patients cope more steadily with symptom fluctuations and supports improved day-to-day comfort.

It is commonly used across conditions characterized by periods of heightened symptoms when reliance on oral corticosteroids (OCS) is needed for control, as it may assist with managing dependence on these systemic medications. This contributes to easing the overall symptom load associated with long-term use of systemic steroids. Fasenra is also applied in managing Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adults. The treatment is relevant for easing symptoms presenting with systemic or localized discomfort and supports the patient during difficult episodes.

---

Quick Fact: Relief for Recurrent Respiratory Events
This medication is commonly used to help with managing the frequency and intensity of asthma attacks and the chronic respiratory symptoms that interfere with daily functioning.

Regulatory References

1. European Medicines Agency Product Information

Fasenra (benralizumab) is an add-on maintenance treatment with strict eligibility defined by regulatory bodies. It is contraindicated in patients with a known hypersensitivity to benralizumab or any excipients in the formulation.

Eligibility by Population

Category	Official Regulatory Status
Age (Asthma)	Approved for adults and adolescents ge 12 years. The US indication extends to children ge 6 years with severe eosinophilic asthma.
Age (EGPA)	Approved for adult patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA).
Use Not Established	Safety and efficacy are not established for use in children under 6 years for severe asthma.
Organ Function	No dose adjustment is required for patients with renal impairment, hepatic impairment, or in the elderly population (ge 65 years).

Limitations and Restrictions

The medicine is not indicated for the treatment of acute asthma exacerbations, acute bronchospasm, or status asthmaticus, as it is strictly a maintenance therapy. Patients with a pre-existing parasitic (helminth) infection must be treated for the infection before initiating Fasenra. Use during pregnancy is not recommended unless the benefit to the mother outweighs the potential risk to the fetus, as monoclonal antibodies can cross the placental barrier.

Interactions with other medicines and products — official regulatory information for Fasenra (Benralizumab)

Interaction Scope

Fasenra is a humanized monoclonal antibody, and its official interaction profile is primarily defined by the documented absence of classical pharmacokinetic interaction pathways. The active ingredient, benralizumab, is cleared by general proteolytic degradation and not by the Cytochrome P450 (CYP) enzyme system or specific drug transporters, such as P-glycoprotein (P-gp). Due to this clearance pathway, Fasenra is not expected to influence the clearance or systemic exposure of co-administered small-molecule drugs, and conversely, these drugs are not anticipated to alter the exposure of benralizumab. No specific interactions with food, alcohol, or herbal products are documented in the official labeling.

---

Official Interaction Statements and Restrictions

The official prescribing information outlines specific administrative restrictions for co-administered medicines and certain patient conditions:

Restriction Type	Official Regulatory Statement
Corticosteroid Tapering	Co-administered systemic or inhaled corticosteroids must not be discontinued abruptly when starting Fasenra therapy. Any dose reduction must be gradual and managed under medical supervision.
Helminth Infection	Patients with pre-existing parasitic (helminth) infections must be treated before starting therapy. If a new infection occurs and does not resolve after anti-helminth medication, Fasenra should be discontinued until the infection resolves.
Contraindication	The medicine is contraindicated in patients with known hypersensitivity to benralizumab or any of its excipients.

Connection to the overall interaction profile

The regulatory documentation establishes that the risk of pharmacokinetic drug-drug interactions is low due to the medicine’s unique degradation pathway. The primary documented constraints relate to the required gradual dose adjustment of corticosteroids and the procedural management of existing parasitic infections.

How Fasenra Works

Fasenra (Benralizumab) operates through a dual-action mechanism targeting the Interleukin-5 receptor alpha ( IL-5Ralpha) system and the cells that express it. The core action involves antagonism combined with Antibody-Dependent Cell-Mediated Cytotoxicity ( ADCC).

Blocking Survival Signals and Activating Cell Destruction

The mechanism begins when Benralizumab binds to IL-5Ralpha on eosinophils and basophils, blocking the receptor and preventing the binding of the cytokine IL-5. This blocks the signaling cascade necessary for the survival and maturation of these cells. Simultaneously, the engineered Fc domain of the antibody activates ADCC by recruiting immune effector cells, primarily Natural Killer ( NK) cells, to the IL-5Ralpha-expressing target cell, resulting in apoptosis (programmed cell death).

Resulting Physiological Depletion of IL-5Ralpha Cells

This dual molecular action—stopping the survival signal while actively destroying the cell—causes a profound and sustained systemic depletion of eosinophils and basophils, including the precursors found in the bone marrow. This reduction in the cellular inflammatory load diminishes the source of toxic mediators and proteins, altering the inflammatory process.

Instruction Map: How to use Fasenra — Official Administration Guidelines

This map outlines the standardized instructions for the use of Fasenra (benralizumab).

---

Administration Scope

Field	Official Instruction
Route of administration	Subcutaneous injection (SC) only, administered into the thigh, abdomen, or upper arm.
Dosing schedule (Adults)	Severe Asthma: 30 mg every 4 weeks for the first 3 doses, then every 8 weeks thereafter. EGPA: 30 mg every 4 weeks continuously.
Preparation requirements	The medicine must be warmed to room temperature for approximately 30 minutes before use. It should be visually inspected and must not be used if cloudy or containing large particles.
Age-group administration rules	Adults and adolescents aged 12 years receive 30 mg. Children 6 to 11 years receive 10 mg if weighing less than 35 kg, or 30 mg if weighing 35 kg or more.
Missed-dose rules	If a dose is missed, it should be administered as soon as possible, and the patient must resume the original regimen; a double dose must not be given.
Special procedural conditions	No dose adjustment is required for older adults or those with renal or hepatic impairment. Corticosteroids should not be discontinued abruptly upon starting Fasenra therapy.

---

Instruction Classifications (High-Level)

Field	Classification
Administration method type	Parenteral (Subcutaneous injection).
Frequency pattern	Intermittent cyclic regimen (initial monthly doses, followed by less frequent maintenance doses).
Use-context constraints	Intended for use under the guidance of a healthcare professional; self-administration requires specific training.

---

Resulting Procedural Structure

Official step sequence:

• The injection is warmed to room temperature and visually inspected.
• The fixed dose (10 mg or 30 mg) is administered via subcutaneous injection into an approved site.
• Dosing frequency follows the initial monthly loading period before transitioning to the longer maintenance interval for asthma, or a continuous four-week interval for EGPA.

Connection to the overall use protocol: The official instructions establish a fixed-dose, fixed-interval protocol that dictates the exact amount, route, and timing of administration for the entire course of treatment. This structure ensures the medicine is consistently introduced beneath the skin according to the specific cyclical schedule. These rules define the standardized patient-facing logistics of using the prescription.

Fasenra (Benralizumab): Recent Clinical Evidence

Clinical trials have evaluated the use of Fasenra (benralizumab) as an add-on maintenance treatment for severe eosinophilic asthma and for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

---

Evidence in Severe Eosinophilic Asthma (SEA)

Major Phase 3 trials, including SIROCCO and CALIMA, assessed benralizumab in adult and adolescent patients (12 years and older) with severe asthma that remained uncontrolled despite high-dose standard therapy. A key finding was the observation of reduced annual asthma exacerbation rates when benralizumab was added to the standard treatment regimen, particularly in patients with a baseline blood eosinophil count of 300 cells/μL or greater. The observed rate reduction was up to 51% in the SIROCCO trial (48 weeks) and up to 28% in the CALIMA trial (56 weeks) compared to placebo.

In addition to the reduction in exacerbation frequency, lung function, measured by the Forced Expiratory Volume in 1 second ( FEV1), showed improvements in these study populations, often noted as early as four weeks after the first dose, and sustained over the treatment period.

The ZONDA trial specifically evaluated patients dependent on oral corticosteroids (OCS). Study results indicated that patients receiving benralizumab achieved a greater median reduction in their daily OCS dose compared to the placebo group while maintaining asthma control.

---

Evidence in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

For EGPA, a Phase 3 trial named MANDARA was conducted. This study provided evidence supporting the use of benralizumab in adult patients with relapsing or refractory EGPA. The primary endpoint assessed the achievement of remission, which was defined by specific criteria including disease-free status and the ability to taper or discontinue OCS use. Observed data showed that a notable percentage of benralizumab-treated patients achieved remission by Week 52, a finding that was comparable to a previously approved biologic treatment for EGPA.

Common questions about Fasenra (FAQ)

---

Q: How quickly does Fasenra start to work after the first injection?

Clinical studies show that the medication can start working early in the treatment process. Specifically, improvements in lung function, often measured by FEV1, have been observed as early as four weeks after the first dose. Official information states that the rapid and profound reduction of inflammatory cells (eosinophils) is generally observed following the first injection.

---

Q: What are the most common side effects people report with Fasenra?

Based on official data from clinical trials, the most commonly reported side effects are headache and pharyngitis (sore throat). Patients are always encouraged to be aware of the full safety information provided by regulatory bodies.

---

Q: Is it normal to feel a stinging or burning sensation at the injection site?

Injection site reactions are a common adverse event documented in the official prescribing information. These reactions may include temporary symptoms like pain, redness, itching, or swelling at the area where the shot was given. While these reactions are common, any persistent or severe symptoms should be discussed with a healthcare professional.

---

Q: What happens if I miss a scheduled Fasenra injection?

If a dose is missed, regulatory guidelines indicate it should be administered as soon as possible. Once the missed dose has been given, the original dosing schedule should be resumed. It is strictly advised that a double dose is not taken to make up for the missed one.

---

Q: Can you take Fasenra if you have high blood pressure?

The official regulatory documents do not list high blood pressure (hypertension) as a specific condition that contraindicates or restricts the use of Fasenra. The need for dose adjustment is not documented for conditions like high blood pressure; however, it is important for patients to review their full medical history with their prescribing doctor.

---

Q: Can Fasenra cause weight gain or weight loss?

Official regulatory prescribing information, which details adverse reactions by body system, does not list changes in weight (gain or loss) among the most common or frequently reported side effects from clinical trials.

---

Q: How long do the effects of a single Fasenra injection last?

The effects of the medication are sustained, which is reflected in the maintenance dosing schedule. For severe asthma, injections are typically given every eight weeks. This extended interval is possible because the medicine causes a profound and sustained reduction in inflammatory cells.

---

Q: How soon can I stop oral steroids after starting Fasenra?

Systemic or inhaled corticosteroids should not be abruptly stopped when starting Fasenra therapy. Regulatory warnings emphasize that any reduction in your steroid dose must be gradual and managed under the direct supervision of a physician.

---

Q: What percentage of people see an improvement in breathing with Fasenra?

Clinical trials consistently showed that patients using Fasenra experienced statistically significant improvements in lung function ( FEV1, a measure of breathing capacity) compared to those on placebo. Additionally, studies showed a notable reduction in the rate of severe asthma attacks (exacerbations), indicating improved breathing control for many users.

---

Q: Does Fasenra help with nighttime asthma symptoms?

Clinical studies focus on key metrics of asthma control, such as reducing exacerbations and improving lung function. While these improvements generally lead to better overall asthma control, specific data on nighttime symptom scores is not a standard feature of the core regulatory label summary.

---

Q: Does Fasenra make you tired or cause fatigue?

While fatigue is not listed as a common side effect in official documents, pyrexia (fever) is listed as a common adverse reaction. Since fever can often be associated with feelings of tiredness, this may be indirectly relevant to feelings of fatigue in some patients.

---

Q: Are there any foods or drinks to avoid while using Fasenra?

The official regulatory documentation on drug interactions states that Fasenra is cleared by the body through a process that is not affected by food, alcohol, or herbal products. Therefore, no specific dietary restrictions are formally documented.

---

Q: Does Fasenra interact with common pain relievers like ibuprofen?

Formal drug interaction studies with medicines like ibuprofen have not been specifically conducted. However, Fasenra is a protein that is cleared via natural degradation, meaning it is not expected to affect the clearance of most small-molecule drugs like common pain relievers or anti-inflammatories.

---

Q: Can you use Fasenra if you are trying to get pregnant?

Official information advises that all patients who are pregnant or are planning to become pregnant should discuss this carefully with their healthcare provider. A pregnancy exposure registry is available to gather data on the outcomes of women who are exposed to Fasenra during pregnancy.

---

Q: Does Fasenra suppress the ability to fight off infections?

Fasenra works by targeting specific inflammatory white blood cells, but official safety warnings note that it may weaken the body's ability to fight off certain types of parasitic (helminth) infections. Patients with pre-existing parasitic infections must be treated for the infection before starting Fasenra.

---

Q: Can Fasenra be self-injected at home?

Yes, self-administration is possible. The medicine is intended for use under the guidance of a healthcare provider. Patients or caregivers may administer the injection at home after receiving proper training from a healthcare professional and if the provider determines it is appropriate for the patient.

---

Q: Does Fasenra affect your ability to drive or operate machinery?

Official regulatory documents specifically state that Fasenra has no or negligible influence on a person's ability to drive a vehicle or operate machinery.

---

Q: Can Fasenra be used for conditions other than asthma?

Fasenra is approved for use as an add-on maintenance treatment for severe eosinophilic asthma and for treating a specific blood vessel condition called eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not indicated for the treatment of other eosinophilic conditions.

---

Q: Does Fasenra interact with allergy medications or antihistamines?

Formal drug interaction studies with these types of medicines have not been specifically conducted. However, because Fasenra is a protein cleared by natural processes, it is not expected to affect the clearance of most small-molecule drugs, including allergy medications and antihistamines.

---

Q: Does Fasenra require any special monitoring or blood tests?

While there are no mandatory routine blood tests related to the drug itself, the regulatory documents recommend that monitoring of patients is necessary after administration, particularly to watch for any immediate or delayed signs of a hypersensitivity reaction.

---

Q: Is the pre-filled syringe or the auto-injector easier to use for Fasenra?

Both the pre-filled syringe and the auto-injector (Fasenra Pen) are available options. The auto-injector is specifically designed for patient or caregiver administration at home and features elements like an audible click and a viewing window to help ensure the injection is successfully completed.

---

Q: Is it true that Fasenra targets a specific cell type?

Yes, this is correct. Fasenra is a highly targeted biologic that binds to the Interleukin-5 receptor alpha (IL-5Ralpha) protein found on the surface of two specific white blood cells: eosinophils and basophils.

---

Q: Can I get a flu shot or other vaccines while on Fasenra?

Regulatory information indicates that the immune response to the seasonal influenza vaccine was specifically studied and found to not be affected by Fasenra treatment. Patients should discuss their specific vaccination needs with their healthcare provider.

---

Q: Does Fasenra have a risk of injection site infections?

While injection site reactions (like pain and redness) are common, the official regulatory documents do not list injection site infections as a specific common or frequently reported adverse reaction in clinical studies.

---

Q: Is Fasenra used for COPD or only for asthma?

Fasenra has official approval and is only indicated for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). It is not indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

---

Q: How does the mechanism of action of Fasenra differ from other biologics?

Fasenra has a dual mechanism of action that sets it apart. It acts as an antagonist to block the IL-5 receptor, and it also recruits immune cells (like Natural Killer cells) to actively destroy the targeted cells through a process called Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). This results in a rapid and near-complete depletion of eosinophils.

---

Q: Are there any known long-term side effects after stopping Fasenra?

While the adverse event profile remained similar during the long-term extension trials, official regulatory documents do not specifically detail known side effects or health impacts that occur after stopping the medication.

---

Q: Will Fasenra reduce my reliance on quick-relief inhalers?

Clinical studies demonstrated that Fasenra effectively reduced the rate of severe asthma exacerbations and improved lung function. This overall improvement in asthma control is consistent with a goal of reducing the frequency of severe symptoms that require quick-relief inhalers.

---

Q: Is Fasenra a long-term treatment?

Yes, Fasenra is intended to be used as a long-term maintenance treatment to control severe eosinophilic asthma. It is not used for acute or sudden breathing problems.

---

Q: What type of doctor usually prescribes Fasenra?

Fasenra is indicated for severe asthma and EGPA, which are specialized conditions. It is typically prescribed by specialists in these conditions, such as a pulmonologist, allergist/immunologist, or rheumatologist (for EGPA).

---

Q: Is it possible for Fasenra to stop working over time?

The official guidelines require that a patient's need to continue therapy be assessed at least annually. This periodic re-evaluation, based on factors like disease severity and exacerbation control, implies that treatment effectiveness should be continually monitored by a doctor.

How to Store and Dispose of Fasenra (benralizumab)

Fasenra is a temperature-sensitive biologic requiring strict adherence to storage and disposal regulations to maintain its stability and ensure safety.

---

Official Storage Conditions

Condition	Requirement
Temperature Range	Store in a refrigerator between 2 C to 8 C (36 F to 46 F).
Prohibited Storage	Do not freeze and do not shake the pen or syringe. Do not expose to heat.
Light Protection	Store in the original carton to protect the solution from light.
Stability Limit	May be kept at room temperature (20 C to 25 C) for a maximum of 14 days; it must be used or discarded after this period.
Safety	Keep all containers out of the sight and reach of children.

---

Disposal Instructions

Used Fasenra Pens and syringes must be placed immediately into an FDA-cleared sharps disposal container. The used pen must not be thrown into household trash or recycled. The full sharps container must be disposed of according to local community guidelines for hazardous medical waste.